Cooper C. Collins
CIK 1485508 · Chief Strategic Officer · last filed 2025-11-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$133.1K
Companies
2
Total Filings
37
Lifetime Open-Market Net
-$19.73M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TXMD | Director | 60,516 | $2.20 | $133.1K | -$2.99M | 24 | 2025-11-05 |
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Chief Strategic Officer | 2,980,727 | — | — | -$16.74M | 12 | 2014-03-05 |
Recent Filings · Page 2 of 4
37 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-07-02 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2020-06-19 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2020-06-10 | TXMD | Buy (P) | +74,000 | $107.3K | EDGAR |
| 2019-06-24 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2019-05-15 | TXMD | Buy (P) | +30,000 | $99.9K | EDGAR |
| 2018-07-05 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2017-06-23 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2016-12-22 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2016-03-14 | TXMD | Buy (P) | +16,000 | $99.7K | EDGAR |
| 2015-12-21 | TXMD | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.